<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p80" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_80{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_80{left:341px;bottom:30px;}
#t3_80{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_80{left:377px;bottom:30px;}
#t5_80{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_80{left:540px;bottom:30px;}
#t7_80{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_80{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_80{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_80{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_80{left:285px;bottom:827px;letter-spacing:-0.37px;word-spacing:0.11px;}
#tc_80{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_80{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_80{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_80{left:1119px;bottom:28px;letter-spacing:0.3px;}
#tg_80{left:36px;bottom:152px;}
#th_80{left:42px;bottom:146px;letter-spacing:0.12px;}
#ti_80{left:45px;bottom:130px;letter-spacing:0.12px;}
#tj_80{left:36px;bottom:119px;}
#tk_80{left:42px;bottom:113px;letter-spacing:0.12px;}
#tl_80{left:313px;bottom:113px;letter-spacing:0.14px;}
#tm_80{left:360px;bottom:113px;}
#tn_80{left:497px;bottom:778px;letter-spacing:0.15px;word-spacing:0.01px;}
#to_80{left:36px;bottom:627px;letter-spacing:-0.09px;}
#tp_80{left:170px;bottom:634px;}
#tq_80{left:178px;bottom:627px;letter-spacing:-0.06px;}
#tr_80{left:36px;bottom:608px;letter-spacing:-0.1px;}
#ts_80{left:80px;bottom:616px;}
#tt_80{left:36px;bottom:406px;letter-spacing:-0.1px;}
#tu_80{left:36px;bottom:228px;letter-spacing:-0.12px;}
#tv_80{left:325px;bottom:627px;letter-spacing:-0.1px;}
#tw_80{left:325px;bottom:608px;letter-spacing:-0.1px;}
#tx_80{left:400px;bottom:616px;}
#ty_80{left:325px;bottom:416px;letter-spacing:-0.09px;}
#tz_80{left:325px;bottom:397px;letter-spacing:-0.1px;}
#t10_80{left:324px;bottom:237px;letter-spacing:-0.09px;}
#t11_80{left:324px;bottom:219px;letter-spacing:-0.1px;}
#t12_80{left:497px;bottom:737px;letter-spacing:-0.11px;}
#t13_80{left:497px;bottom:702px;letter-spacing:-0.1px;}
#t14_80{left:497px;bottom:663px;letter-spacing:-0.11px;}
#t15_80{left:497px;bottom:559px;letter-spacing:-0.09px;}
#t16_80{left:497px;bottom:541px;letter-spacing:-0.09px;}
#t17_80{left:497px;bottom:522px;letter-spacing:-0.1px;}
#t18_80{left:689px;bottom:683px;letter-spacing:-0.08px;}
#t19_80{left:689px;bottom:664px;letter-spacing:-0.09px;}
#t1a_80{left:689px;bottom:646px;letter-spacing:-0.1px;}
#t1b_80{left:786px;bottom:654px;}
#t1c_80{left:689px;bottom:541px;letter-spacing:-0.13px;}
#t1d_80{left:712px;bottom:549px;}
#t1e_80{left:928px;bottom:747px;letter-spacing:-0.09px;}
#t1f_80{left:928px;bottom:729px;letter-spacing:-0.09px;}
#t1g_80{left:928px;bottom:626px;letter-spacing:-0.1px;}
#t1h_80{left:928px;bottom:608px;letter-spacing:-0.09px;}
#t1i_80{left:928px;bottom:589px;letter-spacing:-0.08px;}
#t1j_80{left:1071px;bottom:644px;letter-spacing:-0.09px;}
#t1k_80{left:1071px;bottom:626px;letter-spacing:-0.06px;}
#t1l_80{left:1071px;bottom:608px;letter-spacing:-0.09px;}
#t1m_80{left:1071px;bottom:589px;letter-spacing:-0.1px;}
#t1n_80{left:1071px;bottom:571px;letter-spacing:-0.09px;}
#t1o_80{left:497px;bottom:416px;letter-spacing:-0.09px;}
#t1p_80{left:497px;bottom:397px;letter-spacing:-0.08px;}
#t1q_80{left:643px;bottom:476px;letter-spacing:-0.08px;}
#t1r_80{left:643px;bottom:458px;letter-spacing:-0.1px;}
#t1s_80{left:643px;bottom:362px;letter-spacing:-0.09px;}
#t1t_80{left:643px;bottom:344px;letter-spacing:-0.08px;}
#t1u_80{left:643px;bottom:326px;letter-spacing:-0.1px;}
#t1v_80{left:766px;bottom:412px;letter-spacing:-0.21px;}
#t1w_80{left:766px;bottom:394px;letter-spacing:-0.09px;}
#t1x_80{left:644px;bottom:256px;letter-spacing:-0.1px;}
#t1y_80{left:746px;bottom:263px;}
#t1z_80{left:644px;bottom:237px;letter-spacing:-0.06px;}
#t20_80{left:644px;bottom:219px;letter-spacing:-0.1px;}
#t21_80{left:644px;bottom:201px;letter-spacing:-0.1px;}
#t22_80{left:928px;bottom:246px;letter-spacing:-0.1px;}
#t23_80{left:928px;bottom:228px;letter-spacing:-0.09px;}
#t24_80{left:928px;bottom:210px;letter-spacing:-0.09px;}
#t25_80{left:1071px;bottom:265px;letter-spacing:-0.09px;}
#t26_80{left:1071px;bottom:246px;letter-spacing:-0.06px;}
#t27_80{left:1071px;bottom:228px;letter-spacing:-0.09px;}
#t28_80{left:1071px;bottom:210px;letter-spacing:-0.1px;}
#t29_80{left:1071px;bottom:191px;letter-spacing:-0.09px;}
#t2a_80{left:680px;bottom:152px;}
#t2b_80{left:690px;bottom:146px;letter-spacing:0.12px;}
#t2c_80{left:689px;bottom:130px;letter-spacing:0.12px;}
#t2d_80{left:680px;bottom:119px;}
#t2e_80{left:686px;bottom:113px;letter-spacing:0.12px;word-spacing:-0.06px;}
#t2f_80{left:961px;bottom:113px;}
#t2g_80{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_80{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_80{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_80{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_80{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_80{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_80{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_80{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_80{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s8_80{font-size:15px;font-family:ArialMT_k0;color:#000;}
.s9_80{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.sa_80{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sb_80{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.sc_80{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sd_80{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts80" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg80Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg80" style="-webkit-user-select: none;"><object width="1210" height="935" data="80/80.svg" type="image/svg+xml" id="pdf80" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_80" class="t s0_80">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_80" class="t s1_80">® </span>
<span id="t3_80" class="t s0_80">(NCCN </span>
<span id="t4_80" class="t s1_80">® </span>
<span id="t5_80" class="t s0_80">), All rights reserved. NCCN Guidelines </span>
<span id="t6_80" class="t s1_80">® </span>
<span id="t7_80" class="t s0_80">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_80" class="t s2_80">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_80" class="t s2_80">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_80" class="t s3_80">NCCN Guidelines Version 4.2024 </span>
<span id="tb_80" class="t s3_80">Salivary Gland Tumors </span>
<span id="tc_80" class="t s4_80">NCCN Guidelines Index </span>
<span id="td_80" class="t s4_80">Table of Contents </span>
<span id="te_80" class="t s4_80">Discussion </span>
<span id="tf_80" class="t s5_80">SALI-2 </span>
<span id="tg_80" class="t s6_80">i </span>
<span id="th_80" class="t s7_80">Characteristics of a benign tumor include mobile superficial lobe, slow growth, </span>
<span id="ti_80" class="t s7_80">painless, V and/or VII intact, and no neck nodes. </span>
<span id="tj_80" class="t s6_80">j </span>
<span id="tk_80" class="t s8_80">If incidental N+ disease is present go to </span><span id="tl_80" class="t s9_80">SALI-3</span><span id="tm_80" class="t s7_80">. </span>
<span id="tn_80" class="t s5_80">PATHOLOGY RESULT </span>
<span id="to_80" class="t s5_80">Clinically benign </span>
<span id="tp_80" class="t sa_80">i </span>
<span id="tq_80" class="t s5_80">or </span>
<span id="tr_80" class="t s5_80">T1,T2 </span>
<span id="ts_80" class="t sa_80">j </span>
<span id="tt_80" class="t s5_80">T3,T4a </span>
<span id="tu_80" class="t s5_80">T4b </span>
<span id="tv_80" class="t s5_80">Complete </span>
<span id="tw_80" class="t s5_80">resection </span>
<span id="tx_80" class="t sa_80">k </span>
<span id="ty_80" class="t s5_80">Surgical </span>
<span id="tz_80" class="t s5_80">evaluation </span>
<span id="t10_80" class="t s5_80">No resection possible or </span>
<span id="t11_80" class="t s5_80">resection not recommended </span>
<span id="t12_80" class="t s5_80">Benign </span>
<span id="t13_80" class="t s5_80">or </span>
<span id="t14_80" class="t s5_80">Low grade </span>
<span id="t15_80" class="t s5_80">Adenoid cystic; </span>
<span id="t16_80" class="t s5_80">Intermediate or </span>
<span id="t17_80" class="t s5_80">high grade </span>
<span id="t18_80" class="t s5_80">If tumor spillage or </span>
<span id="t19_80" class="t s5_80">perineural invasion, </span>
<span id="t1a_80" class="t s5_80">consider RT </span>
<span id="t1b_80" class="t sa_80">l </span>
<span id="t1c_80" class="t s5_80">RT </span>
<span id="t1d_80" class="t sa_80">l </span>
<span id="t1e_80" class="t s5_80">Follow-up as </span>
<span id="t1f_80" class="t s5_80">clinically indicated </span>
<span id="t1g_80" class="t s5_80">Follow-up </span>
<span id="t1h_80" class="t sb_80">(FOLL-A, 1 </span>
<span id="t1i_80" class="t sb_80">of 2) </span>
<span id="t1j_80" class="t s5_80">Recurrent </span>
<span id="t1k_80" class="t s5_80">or </span>
<span id="t1l_80" class="t s5_80">Persistent </span>
<span id="t1m_80" class="t s5_80">Disease </span>
<span id="t1n_80" class="t sb_80">(SALI-4) </span>
<span id="t1o_80" class="t s5_80">Cancer </span>
<span id="t1p_80" class="t s5_80">site </span>
<span id="t1q_80" class="t s5_80">Parotid </span>
<span id="t1r_80" class="t s5_80">gland </span>
<span id="t1s_80" class="t s5_80">Other </span>
<span id="t1t_80" class="t s5_80">salivary </span>
<span id="t1u_80" class="t s5_80">glands </span>
<span id="t1v_80" class="t s5_80">Treatment </span>
<span id="t1w_80" class="t sb_80">(SALI-3) </span>
<span id="t1x_80" class="t sc_80" data-mappings='[[2,"fi"]]'>Deﬁnitive RT </span>
<span id="t1y_80" class="t sa_80">l </span>
<span id="t1z_80" class="t s5_80">or </span>
<span id="t20_80" class="t s5_80">Concurrent systemic </span>
<span id="t21_80" class="t s5_80">therapy/RT (category 2B) </span>
<span id="t22_80" class="t s5_80">Follow-up </span>
<span id="t23_80" class="t sb_80">FOLL-A, 1 of </span>
<span id="t24_80" class="t sb_80">2) </span>
<span id="t25_80" class="t s5_80">Recurrent </span>
<span id="t26_80" class="t s5_80">or </span>
<span id="t27_80" class="t s5_80">Persistent </span>
<span id="t28_80" class="t s5_80">Disease </span>
<span id="t29_80" class="t sb_80">(SALI-4) </span>
<span id="t2a_80" class="t s6_80">k </span>
<span id="t2b_80" class="t s7_80">Resection of a clinically benign tumor includes: no enucleation of lateral </span>
<span id="t2c_80" class="t s7_80">lobe and intraoperative communication with pathologist if indicated. </span>
<span id="t2d_80" class="t s6_80">l </span>
<span id="t2e_80" class="t s9_80">Principles of Radiation Therapy (SALI-A)</span><span id="t2f_80" class="t s7_80">. </span>
<span id="t2g_80" class="t sd_80">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
